Nanjing Leads Biolabs says China regulator clears IND for LBL-024 in metastatic colorectal cancer

• Nanjing Leads Biolabs secured China NMPA clearance to start a new clinical trial of PD-L1/4-1BB bispecific LBL-024 in metastatic colorectal cancer.
• The IND supports an open-label, multicenter Phase Ib/II study testing LBL-024 in combination therapy to assess safety, efficacy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260803-12265562), on August 02, 2026, and is solely responsible for the information contained therein.